Additionally, an ROC curve suggested that TNFAIP3 mutation had weak sensitivity for high‐risk T‐ALL (AUC = 53.3%, 95% CI: 48.8%–57.9%) and ETP‐ALL (AUC = 58.3%, 95% CI: 42.0%–74.7%; Figure 4A,B, right panels). This evidence concerns the gene TNFAIP3 and acute lymphoblastic leukemia.